3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Lymphoma
2
Sarcoma
1
Prostatic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Mixed Dementias
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Lewy Body Disease
1
Kidney Neoplasms
1
Dementia, Vascular
1
Dementia
1
Colorectal Neoplasms
1
Cognitive Dysfunction
1
Breast Neoplasms
1
Interventions
Paclitaxel
96
Carboplatin
81
Bevacizumab
62
Gemcitabine
36
liposomal doxorubicin
32
pembrolizumab
30
Topotecan
26
olaparib
23
Taxes
23
niraparib
17
Immunoglobulin G
17
Disulfides
17
Docetaxel
16
Cyclophosphamide
16
Cisplatin
14
Nivolumab
11
rucaparib
10
durvalumab
10
Doxorubicin
9
Albumin-Bound Paclitaxel
8
sargramostim
7
pazopanib
7
fludarabine phosphate
7
fludarabine
7
avelumab
7
Magnetic Resonance Spectroscopy
7
Ifosfamide
7
epacadostat
6
Trabectedin
6
Sorafenib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Ovarian Neoplasms
×
Referral and Consultation
×
Clear all
NCT02821793
2025-07-01
PRIORITY
Institut Bergonié
Completed
346 enrolled
9 charts